Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5660636 | 0.94 | DRD2 (0.46) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| Fumaric Acid SCHEMBL5660640 | 0.94 | DRD2 (0.46) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL5660014 | 0.87 | HTR1A (0.57) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL5660583 | 0.86 | HTR1A (0.52) | HTR1ASLC6A4SIGMAR1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL5660407 | 0.86 | HTR1A (0.56) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL5655955 | 0.86 | HTR2C (0.47) | HTR1ASLC6A4SIGMAR1KCNH2HRH3 | |
| SCHEMBL5661060 | 0.86 | HTR1A (0.53) | DRD2DRD3HTR1ASLC6A4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5660142 | 0.86 | HTR1A (0.51) | HTR1ASLC6A4SIGMAR1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL5658805 | 0.85 | KCNH2 (0.54) | DRD2DRD3HTR1ASIGMAR1KCNH2 | |
| Fumaric Acid SCHEMBL5659182 | 0.81 | HTR1A (0.48) | DRD2DRD4DRD3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | DRD2 402/4885DRD4 498/4885DRD3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.